Snapshot from Aug 18, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Sun Pharma Q1 profit rises 27%
Business earnings report

Sun Pharma Q1 profit rises 27%

Analysis based on 9 articles · First reported Jul 31, 2026 · Last updated Jul 31, 2026

Sentiment
10
Attention
2
Articles
9
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

Sun Pharma's results reflect continued strength in its India and innovative medicines businesses, offsetting US generics pressure, which may support its stock price. The pending Organon acquisition is expected to expand its specialty portfolio and global reach, potentially enhancing long-term growth prospects.

Pharmaceuticals
Event Summary

Sun Pharma Industries reported a 27% year-on-year increase in consolidated net profit to Rs 2,894.79 crore for the first quarter ended June 30, 2026, driven by strong growth in India and its global innovative medicines portfolio. Revenue from operations rose about 10.5% to Rs 15,299 crore. India formulations sales grew 16% to Rs 5,475 crore, accounting for 36.1% of consolidated sales, while global innovative medicines sales rose 12.8% to $351 million. US formulations sales declined 9.7% to $427 million due to weakness in generics, including loss of exclusivity for lenalidomide. The company reported an exceptional charge of Rs 204 crore, including Rs 167 crore related to the proposed acquisition of Organon & Co., which shareholders have approved and is expected to close in early 2027. Sun Pharma also highlighted recent semaglutide approvals in India, Brazil and South Africa, and continued R&D investment with five novel entities in clinical development. The stock closed slightly lower on the Bombay Stock Exchange.

Key Actions
90 Sun Pharma reported net profit
80 Organon & Co. approved acquisition Sun Pharma
60 Sun Pharma received semaglutide approvals
50 Sun Pharma incurred acquisition costs
40 Sun Pharma filed ANDAs United States — Food and Drug Administration
Entities Involved
stock
Sun Pharma
Sun Pharma reported a 27% rise in Q1 net profit and 10.5% revenue growth, driven by India and innovative medicines, while US generics declined. The company is progressing on its Organon acquisition, expected to close in early 2027.
Importance 100.0 Sentiment 10.0
cnt
India
India formulations sales grew 16% to Rs 5,475 crore, accounting for 36.1% of consolidated sales, and Sun Pharma maintained its position as the largest pharmaceutical company in India with market share rising to 8.5%.
Importance 70.0 Sentiment 20.0
cnt
United States
US formulations sales declined 9.7% to $427 million due to weakness in generics, including loss of exclusivity for lenalidomide, partially offset by growth in innovative medicines.
Importance 60.0 Sentiment -10.0
stock
Organon & Co.
Organon shareholders approved the proposed acquisition by Sun Pharma, which is on track to close in early 2027, expected to strengthen Sun's specialty portfolio.
Importance 60.0 Sentiment 20.0
govactor
United States — Food and Drug Administration
Sun Pharma filed three ANDAs and received approvals for six during the quarter, with 119 ANDAs awaiting FDA approval, reflecting ongoing regulatory engagement.
Importance 40.0 Sentiment 0.0
per
Kirti Ganorkar
As Managing Director, Kirti Ganorkar commented on the quarter's performance, highlighting growth in India and innovative medicines, and the progress of the Organon acquisition.
Importance 30.0 Sentiment 0.0
cnt
Brazil
Sun Pharma received semaglutide approval in Brazil, underscoring its capabilities in complex peptide products and expanding its global footprint.
Importance 20.0 Sentiment 10.0
cnt
South Africa
Sun Pharma received semaglutide approval in South Africa, contributing to its international growth.
Importance 20.0 Sentiment 10.0
exch
Bombay Stock Exchange
Sun Pharma's shares declined slightly on the BSE following the results announcement.
Importance 10.0 Sentiment 0.0
curr
India — Indian rupee
Financial results were reported in India — Indian rupees, with net profit of Rs 2,894.79 crore and revenue of Rs 15,299 crore.
Importance 10.0 Sentiment 0.0
curr
United States — United States dollar
US and international sales were reported in US dollars, with US formulations at $427 million and innovative medicines at $351 million.
Importance 10.0 Sentiment 0.0
Relationships
Sun Pharma related ↔ India
Sun Pharma related ↔ United States
Sun Pharma related ↔ Organon & Co.
Sun Pharma related ↔ United States — Food and Drug Administration
India strategic partners ↔ United States India views the US as a strategic partner for defense, technology, and regional security, despite facing recent US tarif
India related ↔ United States — Food and Drug Administration
India related ↔ Brazil
India related ↔ South Africa
India related ↔ Bombay Stock Exchange
United States related ↔ United States — Food and Drug Administration
United States related ↔ Brazil
United States related ↔ South Africa
United States related ↔ Bombay Stock Exchange
United States — Food and Drug Administration related ↔ Brazil
Brazil related ↔ South Africa
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.